Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (322)	6/24/1999 2:23:00 PM
From: NeuroInvestment	Read Replies (3) \| Respond to of 496

Your complaint about the pace of the neuroimmunophilin program is well taken--it is entirely under AMGN's control, as is the lack of information available--but there are a number of inaccuracies in your post. 1) Other small molecule neurotrophin programs are being run by Cephalon (about to enter Ph1), Vertex (in Ph1), Myelos (preclinical), and NeoTherapeutics--who finished one small Ph2 but won't finish their larger (400pt) one until the end of 99. I probably have omitted one, but I have heard nothing of a US Big Pharma or 'Austrian' competitor--the Regeneron/Glaxo collaboration has not made much progress. 2) There is plenty of cocaine addiction competition as well--Allelix (Canada), NeuroSearch (Denmark), Drug Abuse Sciences (US), and Cantab,the UK company that bought out Immulogic's cocaine program. Just wanted to clarify. NeuroInvestment (www.neuroinvestment.com)